Specifications TableSubjectCardiology and Cardiovascular MedicineSpecific subject areaA meta-analysis reporting the relative risk of developing adverse events related to amiodarone compared to placeboType of dataTables\
Figures\
Raw data (supplement)How data were acquiredWe searched PubMed, Google Scholar, the Cochrane Central Register for RCTs, and [ClinicalTrials.gov](http://ClinicalTrials.gov){#intref0010} for studies that evaluated amiodarone use irrespective of indication or efficacy of amiodarone therapyData formatRaw, Analyzed,\
FilteredParameters for data collectionPatients who took amiodarone for prevention and/or treatment of ventricular or atrial arrhythmias.Description of data collectionWe searched PubMed, Google Scholar, the Cochrane Central Register for RCTs, and [ClinicalTrials.gov](http://ClinicalTrials.gov){#intref0015} for studies that evaluated amiodarone use irrespective of indication or efficacy of amiodarone therapy. Key search terms used were amiodarone, adverse events, side effects, placebo, atrial fibrillation, atrial flutter, ventricular tachycardia, arrhythmias, liver, hepatic, skin, thyroid, eye, and lung, and pulmonary. Bibliographies of retrieved studies were hand-searched to identify additional relevant studies.Data source locationData from randomized controlled trials.Data accessibilityWith the article, and the supplement.Related research articleRuzieh M, Moroi MK, Aboujamous NM, Ghahramani M, Naccarelli GV, Mandrola J, Foy AJ. Meta-Analysis Comparing the Relative Risk of Adverse Events for Amiodarone Versus Placebo. Am J Cardiol. 2019. pii: S0002-9149(19)31046-X. [https://doi.org/10.1016/j.amjcard.2019.09.008](10.1016/j.amjcard.2019.09.008){#intref0020}. \[Epub ahead of print\]**Value of the Data**•This dataset provides detailed description of the adverse events and its relative risk in patients taking amiodarone compared to placebo. This is very important for the medical community as amiodarone is one of commonly used drugs to treat atrial fibrillation.•Medical providers who are prescribing or managing patients taking amiodarone as well as researchers interested in assessing amiodarone related adverse events.•Further analysis could be performed to determine how different amiodarone loading and maintenance regimens could affect the development of amiodarone related adverse events.•Understanding the nature and the rate of amiodarone related adverse events will help physicians develop appropriate screening and monitoring strategies for these events.

1. Data {#sec1}
=======

The raw dataset contains the number of events and number of patient-year for the amiodarone and placebo arm of each study (reads in xlsx format, each organ system in a separate sheet). Patients' characteristics are summarized in [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}. The number and incident rate of events are listed in [Table 4](#tbl4){ref-type="table"}. The rate of adverse events in the amiodarone arm for each organ system, and the rate of drug discontinuation compared to placebo are illustrated in [Fig. 1](#fig1){ref-type="fig"}, [Fig. 2](#fig2){ref-type="fig"}, [Fig. 3](#fig3){ref-type="fig"}, [Fig. 4](#fig4){ref-type="fig"}, [Fig. 5](#fig5){ref-type="fig"}, [Fig. 6](#fig6){ref-type="fig"}, [Fig. 7](#fig7){ref-type="fig"}, [Fig. 8](#fig8){ref-type="fig"}, [Fig. 9](#fig9){ref-type="fig"}.Table 1Baseline patient characteristics. Forty-three randomized control trials \[[@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20]\] were studied, and 11,395 patients were included (5792 patients in the amiodarone group, 5603 patients in the placebo group). Average age was 62.0 years for patients receiving amiodarone and 62.3 years for patients receiving placebo. Follow up time ranged from 1 week--6 months for studies with follow up \< 12 months. Indications for amiodarone therapy were suppression of atrial and ventricular arrhythmias, and maintenance dose for amiodarone ranged from 200 to 600 mg daily. Raw data for the adverse events is provided in the supplement material.Table 1Amiodarone armPlacebo armFirst authorYearMedical conditionAverage Ejection fractionPercent with IHDReason for interventionMean\
follow-up\
(days)Average Load\
Dose (mg/day)Load\
(\# of days)Average Maintenance Dose (mg/day)Maintenance\
(\# of days)No.\
Of\
PtsMean age (yrs)Male Gender (%)No.\
Of\
PtsMean age (yrs)Male Gender (%)Greco1989Patients with anterior MINA100%Reduce mortality and morbidityUntil discharge10--20 mg/kg1N/AN/A15954851605587Hamer1989Congestive heart failure18%60%Arrhythmia control, exercise tolerance and ventricular function1803871802001501670N/A1466N/AHohnloser1991Post CABGNA100%Suppression of SVT and ventricular arrhythmias411254N/AN/A395976.9385973.7Meyer1993Stable angina59%100%Limiting angina pectoris6040030200503261N/A3158N/AMahmarian1994Systolic heart failure and NSVT24%49%Suppression of ventricular arrhythmias904223050 or 100543253.577.5165181Donovan1995Patients with recent-onset AFNA48%Restoration of sinus rhythmUntil discharge7 mg/kg1N/AN/A3256N/A3259N/AGalve1996Newly diagnosed AFNANARhythm control151200 + 5 mg/kg1N/AN/A506054506156Gentile1996Elderly patients with systolic heart failure\<40%61%Reduce sudden cardiac death180400301001502471N/A2271N/ADaoud1997Patients undergoing open heart surgery48%60%Prevention of post-op AF30200--100013 ± 7N/AN/A645768.8606766.7Kochiadakis1998Patients with recent onset AF50%NARestoration of sinus rhythm12100 + 20 mg/kg1N/AN/A486356496551Cotter1999Patients with paroxysmal AFMajority \<45%43%Restoration of sinus rhythm3030001N/AN/A5064.548506838Kochiadakis1999Patients with persistent AF50%NARestoration of sinus rhythm30460 + 20 mg/kg28N/AN/A336448.5346347.1Redle1999Patients undergoing CABG49%100%Prevention of post-op AF1043011N/AN/A736383.57064.581.4Bianconi2000Patients with AF or AFLNA15%Acute termination of AF or flutter3--75 mg/kg1N/AN/A546357546654Elizari2000Patients with acute MINA100%Reduce morbidity/mortality1809003N/AN/A54260.380.653160.575.1Lee2000Patients undergoing CABG59%100%Prevention of post-op AF18150 + 0.4/kg8N/AN/A746654766555Peuhkurinen2000Patients with recent-onset AF63%21%Restoration of sinus rhythm130 mg/kg1N/AN/A315681316265Vardas2000Patients with AF51%NARestoration of sinus rhythm3060028N/AN/A1086449.11006549Giri2001Patients undergoing CABG, valve or combined43%98%Prevention of post-op AF910006; 10N/AN/A12072.77810072.574Maras2001Patients undergoing CABG44%100%Prevention of post-op AF73258N/AN/A15958.38015657.376White2002Patients undergoing open heart surgery43%35%Prevention of post-op AF21--421200--1400\>10; \>6N/AN/A12072.678.310072.574Yagdi2003Patients undergoing CABG48%100%Prevention of post-op AF30400-600 + 10/kg2; 5; 5N/AN/A7759.380.58061.173.7Auer2004Patients undergoing open heart surgery69%64%Prevention of post-op AF126679N/AN/A636458.7656358.5Mitchell2005Patients undergoing CABG, valve replacement, repair58%75%Prevention of post-op atrial tachyarrhythmia1310 mg/kg13N/AN/A29961.382.630261.981.8Alcalde2006Patients undergoing CABG53%100%Prevention of post-op AF & AFL1018001--3N/AN/A4661634761.170.2Budeus2006Patients undergoing CABG63%100%Prevention of post-op AF0.56407N/AN/A5564.987.35566.776.4Zebis2007Patients undergoing CABG55%100%Prevention of post-op AF3012005N/AN/A12567861256780Gu2009Patients undergoing off-pump CABG61%100%Prevention of post-op AF21200 + 70 mg/kg17N/AN/A10073.67511074.272Balla2011Newly diagnosed AFNANARhythm control for AF130 mg/kg1N/AN/A4058.972.54058.660Khitri2012AF, AFL59%15%Rhythm control90330302006010864.973.116262.464.9Riber2013Lung cancer surgeryNA2%Prevention of post-op AF3012005N/AN/A12266491206747Darkner2014AF patients undergoing RFA50%7%Rhythm control after ablation180400302002610462811086186[^1]Table 2Baseline patient characteristics. Forty-three randomized control trials \[[@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20]\] were studied, and 11,395 patients were included (5792 patients in the amiodarone group, 5603 patients in the placebo group). Average age was 62.0 years for patients receiving amiodarone and 62.3 years for patients receiving placebo. Follow up time ranged from 12--54 months in studies with follow up ≥ 12 months. Indications for amiodarone therapy were suppression of atrial and ventricular arrhythmias, and maintenance dose for amiodarone ranged from 200 to 600 mg daily. Raw data for the adverse events is provided in the supplement material.Table 2Amiodarone armPlacebo armFirst authorYearMedical conditionAverage ejection fractionPercent with IHDReason for interventionMean follow-up (months)Average Load dose (mg/day)Average Load (day)Average maintenance dose (mg)Average maintenance (days)No. of PtsMean age (year)Male Gender (%)No. of PtsMean age (year)Male Gender (%)Nicklas1991Heart failure and frequent ventricular ectopy20%52%Reduce sudden cardiac death1240028200215495683.7525986.5Ceremuzynski1992Post MIMajority \> 40%100%Reduce mortality and ventricular arrhythmias128007200--40030630559.471.130858.668.2Singh\[36\]1995Patients with CHF and vent arrhythmia\<40%71%Improve mortality458001432812463366599.133866.198.8Cairns1997Survivors of MI with frequent or repetitive PVCsNA100%Resuscitated ventricular fibrillation or arrhythmic death21.520/kg14200--400365--7306066482.55966482Julian1997Survivors of MI and EF ≤ 40%30%35%All-cause mortality21450112200253--61874359.683.874360.284.9Singh1997Patients with CHF, COPD and patients undergoing surgery25--30%NAEvaluate pulmonary toxicity4580014300--400365--162026965N/A25065.8N/AKochiadakis2000Paroxysmal AF55%NARhythm control2212.5/kg142007206563.252.36062.851.7Channer2004Persistent AF undergoing DCCV59%30%Rhythm control5480014200364616677386879Vora2004Patients with chronic rheumatic AF56%NARhythm or rate control12600102003554839.547.9483845.8Singh2005Persistent AF50%25%Rhythm control12--5470028200--300\>36526767.199.313767.799.3Vilvanathan2016AF in patients post BMV58%1%Rhythm control for AF12500282003654438.820.54537.6234.1[^2]Fig. 1Pulmonary adverse events. "Total" represents total events per 10,000 person-years. The incident rate of pulmonary adverse events per 10,000 person-years was higher in the amiodarone group versus placebo (129 vs 74; RR: 1.77; 95% CI \[1.24--2.52\], P = 0.002, 1^2^: 0%).Fig. 1Fig. 2Thyroid adverse events. "Total" represents total events per 10,000 person-years. The incident rate of thyroid adverse events per 10,000 person-years was higher in the amiodarone group versus placebo (201 vs 42; RR: 4.44; 95% CI \[2.87--6.89\], P \< 0.001, 1^2^: 0%).Fig. 2Fig. 3Liver adverse events. "Total represents total events per 10,000 person-years. Liver adverse events were rare, but the rate of liver adverse events per 10,000 person-years was still higher in the amiodarone group versus placebo (54 vs 25; RR: 2.27; 95% CI \[1.20--4.29\], P = 0.01, I^2^: 0%).Fig. 3Fig. 4Cardiac adverse events. "Total" represents total events per 10,000 person-years. Cardiac adverse events were the most commonly reported adverse events for both groups. The incident rate of cardiac adverse events per 10,000 person-years was higher in patients receiving amiodarone versus placebo (771 vs 450; RR: 1.94; 95% CI \[1.39--2.71\], P = 0.0001, I^2^: 23%).Fig. 4Fig. 5Skin adverse events. "Total" represents total events per 10,000 person-years. The incident rate of skin adverse events was higher in the amiodarone group versus placebo (81 vs 23; RR: 1.99; 95% CI \[1.04--3.78\], P = 0.04, I^2^: 0%).Fig. 5Fig. 6Gastrointestinal adverse events. "Total" represents total events per 10,000 person-years. The incident rate of gastrointestinal adverse events was higher in patients receiving amiodarone compared to those receiving placebo (336 vs 212; RR: 1.63; 95% CI \[1.18--2.24\], P = 0.003, I^2^: 14%).Fig. 6Fig. 7Neurological adverse events. "Total" represents total events per 10,000 person-years. The incident rate of neurological adverse events per 10,000 person-years was higher in the amiodarone group versus placebo (140 vs 76; RR: 1.93; 95% CI \[1.41--2.65\], P \< 0.001, 1^2^: 0%).Fig. 7Fig. 8Ocular adverse events. "Total" represents total events per 10,000 person-years. The incident rate of ocular adverse events per 10,000 person-years was higher in patients receiving amiodarone versus placebo; however, this never reached statistical significance (37 vs 10; RR: 3.01; 95% CI \[0.87--10.36\], P = 0.08, I^2^: 30%).Fig. 8Fig. 9Rates of drug discontinuation. "Total" represents total events per 10,000 person-years. The incident rate of drug discontinuation secondary to side effects per 10,000 person-years was higher in the amiodarone group versus placebo (1614 vs 896; RR: 1.79; 95% CI \[1.45--2.19\], P \< 0.001, I^2^: 43%).Fig. 9

2. Experimental design, materials, and methods {#sec2}
==============================================

The protocol was developed by three authors (M.M., M.R., A.F.) and revised by all authors.

PubMed, Google Scholar, the Cochrane Central Register for randomized controlled trials, and [ClinicalTrials.gov](http://ClinicalTrials.gov){#intref0025} were searched for studies that analyzed the use of amiodarone regardless of indication or efficacy of therapy (latest search was conducted on October 10, 2018). Articles were identified using key search terms: amiodarone, adverse events, side effects, placebo, atrial fibrillation, atrial flutter, ventricular tachycardia, arrhythmias, liver, skin, thyroid, eye, and lung. References of all identified studies were also hand-searched for inclusion to identify additional relevant studies \[[@bib1]\].

All articles were then independently reviewed for inclusion in this analysis by two authors (M.M., M.R.). Inclusion criteria were: 1) randomized control trial, 2) documentation of adverse events and drug discontinuation due to adverse events, 3) presence of placebo arm. Data on sample size, follow up, and outcomes were then extracted. Discrepancies were discussed and resolved by consensus.

Primary outcomes of this analysis were pulmonary, hepatic, thyroid, ocular, cardiac, skin, and neurological adverse events, as well as drug discontinuation related to adverse side effects. Specific adverse events within each organ system were also reported. All adverse events were presented as incident rate per 10,000 person-years.

The Cochrane Risk of Bias table and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) System were utilized to determine risk of bias and quality of the outcomes in all trials incorporated into this analysis ([Table 3](#tbl3){ref-type="table"}).Table 3Risk of bias. Majority of trials included in this analysis were double blinded, decreasing both performance and detection biases.Table 3[^3]Table 4Number of events, incident rate, and relative risk of specific adverse events for amiodarone compared to placebo.Table 4organ systemFollow up ≥ 12 months, No. of events (events/10,000 patient year)All, No. of events (events/10,000 patient year)Amiodarone armPlaceboRR (95% CI), P valueAmiodarone armPlaceboRR (95% CI), P valuePulmonary adverse eventsPulmonary fibrosis8 (13)6 (11)8 (12)6 (11)Cough0 (0)0 (0)1 (1)0 (0)Lung infiltrates0 (0)0 (0)1 (1)0 (0)Unspecified77 (124)40 (70)77 (115)40 (65)**Total85 (136)46 (81)1.74 (1.21**--**2.50), 0.00387 (129)46 (74)1.77 (1.24**--**2.52), 0.002**Thyroid adverse eventsClinical hyperthyroidism19 (36)4 (8)19 (33)5 (9)Clinical hypothyroidism27 (52)0 (0)27 (47)0 (0)Subclinical change in TFT13 (25)3 (6)40 (70)8 (15)Unspecified24 (46)5 (11)29 (51)9 (17)**Total83 (159)12 (25)5.32 (2.99**--**9.44),** \< **0.001115 (201)22 (42)4.44 (2.87**--**6.89),** \< **0.001**Liver adverse eventsLiver failure0 (0)0 (0)0 (0)0 (0)Elevated liver enzymes8 (15)3 (6)10 (18)5 (10)Unspecified21 (40)8 (17)21 (37)8 (15)**Total29 (56)11 (23)2.42 (1.23**--**4.74), 0.0131 (54)13 (25)2.27 (1.20**--**4.29), 0.01**Cardiac adverse eventsBradyarrhythmias100 (192)34 (72)267 (468)128 (244)Hypotension0 (0)0 (0)98 (172)65 (124)Long QT5 (10)0 (0)18 (32)0 (0)Torsade de pointes0 (0)0 (0)0 (0)0 (0)Worsening heart failure1 (2)1 (2)5 (9)5 (10)Unspecified conduction disease0 (0)0 (0)46 (81)32 (61)Unspecified0 (0)0 (0)6 (11)6 (11)**Total106 (203)35 (74)2.76 (1.91**--**3.98),** \< **0.001440 (771)236 (450)1.94 (1.39**--**2.71)** \< **0.001**Skin adverse eventsBlue/gray discoloration of skin2 (4)3 (6)2 (4)3 (6)Photosensitivity1 (2)0 (0)11 (19)0 (0)Unspecified rash/flushing21 (40)9 (19)33 (58)9 (17)**Total24 (46)12 (25)1.51 (0.73**--**3.11), 0.2646 (81)12 (23)1.99 (1.04**--**3.78), 0.04**GI adverse eventsDyspepsia/nausea/vomiting20 (38)16 (34)122 (214)74 (141)Diarrhea0 (0)0 (0)8 (14)4 (8)Unspecified35 (67)25 (53)62 (109)33 (63)**Total55 (105)41 (86)1.36 (0.91**--**2.04), 0.14192 (336)111 (212)1.63 (1.18**--**2.24), 0.003**Neuro adverse eventsAtaxia or gait disturbances17 (33)6 (13)17 (30)6 (11)Headache0 (0)0 (0)25 (44)17 (32)Dizziness0 (0)0 (0)7 (12)4 (8)Tremor2 (4)0 (0)2 (4)0 (0)Peripheral neuropathy0 (0)0 (0)1 (2)0 (0)Unspecified29 (56)13 (27)29 (51)13 (25)**Total48 (92)19 (40)2.35 (1.38**--**4.00), 0.00281 (140)40 (76)1.93 (1.41**--**2.65),** \< **0.001**Ocular adverse eventsCorneal microdeposits9 (17)0 (0)9 (16)0 (0)Blurred vision0 (0)0 (0)1 (2)0 (0)Blue vision spots0 (0)0 (0)1 (2)0 (0)Unspecified10 (19)5 (11)10 (18)5 (10)**Total19 (36)5 (11)4.41 (0.48**--**40.86), 0.1921 (37)5 (10)3.01 (0.87**--**10.36), 0.08Drug discontinuation552 (1230)284 (650)2.01 (1.46**--**2.78),** \< **0.001795 (1614)431(896)1.79 (1.45**--**2.19),** \< **0.001**

RevMan version 5.3 (The Nordic Cochrane Center, The Cochrane Collaboration; Copenhagen, Denmark) was used to conduct the primary analysis. Relative risk (RR) was determined for all studies using the Mantel-Haenszel random effects model with 95% confidence interval (CI) to establish the likelihood of adverse events. A secondary analysis was also performed to determine the RR for studies with follow up \< 12 months and ≥12 months. Sensitivity analyses were used to show the robustness of the results. Heterogeneity was calculated using I^2^, a value which represents the percentage of variability in the effect risk estimate among studies due to heterogeneity rather than chance (I^2^ \<25% considered as low, I^2^ between 25% and 75% as intermediate, I^2^ \>75% considered as high). Begg\'s funnel plots method was utilized to investigate potential publication bias. A p-value of \<0.05 was used to determine statistical significance.
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The following is the Supplementary data to this article:Multimedia component 1Multimedia component 1

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.dib.2019.104835>.

[^1]: **AF**: Atrial fibrillation, **AFL:** Atrial flutter, **CABG:** Coronary artery bypass graft, **IHD:** Ischemic heart disease, **MI:** myocardial infarction, **NA:** Not available, **NSVT:** Non-sustained ventricular tachycardia, **RFA:** Radiofrequency ablation.

[^2]: **AF**: Atrial fibrillation, **BMV:** balloon mitral valvuloplasty, **CHF:** congestive heart failure, **COPD:** chronic obstructive pulmonary disease, **DCCV:** direct current cardioversion, **EF:** Ejection fraction, **IHD:** Ischemic heart disease, **MI:** myocardial infarction, **NA:** Not available, **PVC:** premature ventricular contraction.

[^3]: Highlighted are studies with follow up ≥ 12 months.
